Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H2 2016’, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever)

The report reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Lassa Fever (Lassa Hemorrhagic Fever) therapeutics and enlists all their major and minor projects

The report assesses Lassa Fever (Lassa Hemorrhagic Fever) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arno Therapeutics Inc

Celgene Corp

Etubics Corp

Kineta Inc

Profectus BioSciences Inc

SIGA Technologies Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Lassa Fever (Lassa Hemorrhagic Fever) Overview 7

Therapeutics Development 8

Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Overview 8

Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis 9

Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Development by Companies 10

Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Investigation by Universities/Institutes 11

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Products Glance 12

Early Stage Products 12

Lassa Fever (Lassa Hemorrhagic Fever) - Products under Development by Companies 13

Lassa Fever (Lassa Hemorrhagic Fever) - Products under Investigation by Universities/Institutes 14

Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development 15

Arno Therapeutics Inc 15

Celgene Corp 16

Etubics Corp 17

Kineta Inc 18

Profectus BioSciences Inc 19

SIGA Technologies Inc 20

Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

AR-12 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

CC-11050 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

DEF-201 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

FBH-003 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

KIN-1400 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

lassa fever vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

lassa fever vaccine - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

lassa fever vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

LHF-535 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ML-29 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Monoclonal Antibodies for Lassa Fever - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibodies for Viral Infections - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules for Lassa Fever - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ST-193 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects 50

Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones 51

Featured News & Press Releases 51

May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials 51

Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals 51

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2016 8

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Arno Therapeutics Inc, H2 2016 15

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Celgene Corp, H2 2016 16

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Etubics Corp, H2 2016 17

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Kineta Inc, H2 2016 18

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Profectus BioSciences Inc, H2 2016 19

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by SIGA Technologies Inc, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Lassa Fever (Lassa Hemorrhagic Fever) – Dormant Projects, H2 2016 50

List of Figures

List of Figures

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2016 8

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Top 10 Targets, H2 2016 22

Number of Products by Stage and Top 10 Targets, H2 2016 22

Number of Products by Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports